Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The Great Pyramids of Egypt have been the source of fascination and mysticism for generations, with their daunting structures ...